Article Speculates AMAG Pharmaceuticals (AMAG) Could Be A Takeover Target
Tweet Send to a FriendGet Alerts AMAG Hot Sheet
Up)
Trade AMAG Now!
TheStreet.com's biotech guru, Adam Feuerstein, speculates that AMAG Pharmaceuticals (Nasdaq: AMAG) could be the target of a takeover, following last week's approval of Feraheme for intravenous use as an iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease.
Feuerstein contends, ... the changing landscape for treatment of dialysis and pre-dialysis patients, especially the specter of Medicare dialysis bundling looming in the near future, also means that incumbent players in this market need to take big steps to ensure their future success.
According to Feuerstein, some potential suitors for AMAG includes Genzyme (Nasdaq: GENZ), Amgen (Nasdaq: AMGN), Johnson & Johnson (NYSE: JNJ) and Davita (NYSE: DVA).
Feuerstein contends, ... the changing landscape for treatment of dialysis and pre-dialysis patients, especially the specter of Medicare dialysis bundling looming in the near future, also means that incumbent players in this market need to take big steps to ensure their future success.
According to Feuerstein, some potential suitors for AMAG includes Genzyme (Nasdaq: GENZ), Amgen (Nasdaq: AMGN), Johnson & Johnson (NYSE: JNJ) and Davita (NYSE: DVA).
You May Also Be Interested In
- Despite Outside Interest, Tumblr and Yahoo! (YHOO) Are in Lockup (MSFT) (FB)
- JCPenney (JCP) Meeting Peer Performace Could Provide for Prodigious Profits
- Amarin's (AMRN) Vascepa Not in FDA Orange Book for April
Create E-mail Alert Related Categories
Insiders' Blog, Rumors
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
